Frank Wade
Family Medicine · Magee, MSNPI 1619934940
Payments from drug & device makers
Across 127 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$355
- Boehringer Ingelheim$322
- Novo Nordisk$314
- Lilly USA, LLC$233
- Astellas Pharma US Inc$95
- AstraZeneca$79
- plus $574 from 16 others
What the payments were for
- Food & beverage$1,973100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $355 |
| Boehringer Ingelheim | 18 | $322 |
| Novo Nordisk | 23 | $314 |
| Lilly USA, LLC | 14 | $233 |
| Astellas Pharma US Inc | 6 | $95 |
| AstraZeneca | 5 | $79 |
| Amgen | 5 | $70 |
| Merck | 4 | $66 |
| GSK | 4 | $66 |
| Xeris Pharmaceuticals, Inc. | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Eisai Inc. | 3 | $42 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Avanir Pharmaceuticals, Inc. | 2 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Inari Medical, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $13 |
How this compares
$1,973 in reported general payments places this provider in the 70th percentile of 971 family medicine providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $150,762 |
| JardianceEmpagliflozin | 155 | $133,985 |
| EliquisApixaban | 151 | $130,571 |
| FarxigaDapagliflozin Propanediol | 68 | $50,470 |
| TrulicityDulaglutide | 48 | $44,548 |
| VraylarCariprazine Hcl | 31 | $43,368 |
| MounjaroTirzepatide | 39 | $38,600 |
| LinzessLinaclotide | 38 | $31,515 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $30,732 |
| JanuviaSitagliptin Phosphate | 35 | $27,594 |
| XareltoRivaroxaban | 32 | $19,820 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $13,809 |
| EntrestoSacubitril/Valsartan | 13 | $13,729 |
| MyrbetriqMirabegron | 16 | $12,984 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $12,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $314 | $150,762132 claims |
| Boehringer IngelheimJardiance | $322 | $133,985155 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $233 | $83,14787 claims |
| AbbVieVraylar, Linzess, Synthroid | $355 | $78,648129 claims |
| AstraZenecaFarxiga, Symbicort | $79 | $63,040120 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $66 | $35,67963 claims |
| MerckJanuvia | $66 | $27,59435 claims |
| NovartisEntresto | $17 | $13,72913 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $12,98416 claims |
| Sanofi-aventis U.S. LLCLantus | $35 | $2,60015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Magee
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.